MedWatch

Lundbeck not worried about partner's problems

In the short run, Lundbeck will not be affected by the partner Vernalis' financial troubles. Vernalis has had to closed its business in the US and has begun selling-off parts of the parent company. "Until we hear differently, we continue as before," says Lundbeck.

Foto: /ritzau/Jens Dresling/

The future of Lundbeck's UK partner, pharmaceutical company Vernalis, is unknown as the company is currently closing down its business in the US and is looking for someone to purchase the parent company in the UK.

In spite of everything it will not - in the short term at least - have an impact on Lundbeck's partnership with Vernalis, who has developed a fragment and structure-based drug discovery platform.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

EU-lande blåstempler nye beføjelser til agentur

Det europæiske center for sygdomsforebyggelse og -kontrol, ECDC, får nu nye muskler til kontrol og netværksopbygning i kampen mod fremtidens epidemier. ”Dagens aftale er lig med state-of-the-art overvågning,” siger EU-topfolk.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier